Cargando…
The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
BACKGROUND: Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients with platinum-resistant recurrent ovarian cancer. In this retrospective analysis, we evaluated the usage patterns of be...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520859/ https://www.ncbi.nlm.nih.gov/pubmed/34308512 http://dx.doi.org/10.1007/s10147-021-01996-8 |
_version_ | 1784584770128183296 |
---|---|
author | Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke |
author_facet | Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke |
author_sort | Sekine, Masayuki |
collection | PubMed |
description | BACKGROUND: Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients with platinum-resistant recurrent ovarian cancer. In this retrospective analysis, we evaluated the usage patterns of bevacizumab administered for platinum-resistant recurrent ovarian cancer. METHODS: We obtained clinical data from 155 Japanese medical facilities between November 2013 and December 2018 via a survey. Items included the number of cases of platinum-resistant recurrent ovarian cancer treated with bevacizumab according to dosage. For regimens including bevacizumab 10 mg/kg Q2W, additional information was requested relating to concomitantly administered agents, and the efficacy and safety of the regimen. RESULTS: Of 1739 bevacizumab-containing regimens reported in 1633 patients with recurrent ovarian cancer, 264 used 10 mg/kg Q2W. The overall response rate (ORR) with this regimen was 26.1%. Response rates varied according to regimen and were particularly favorable when bevacizumab 10 mg/kg Q2W was administered with paclitaxel (ORR, 53.0%) versus liposomal doxorubicin (15.0%; P < 0.0001) and irinotecan (7.7%; P < 0.028). The most frequent Grade ≥ 3 adverse events associated with bevacizumab 10 mg/kg Q2W were neutropenia (11.7%) and hypertension (11.7%). The most frequent bevacizumab-associated Grade ≥ 3 adverse events with bevacizumab plus paclitaxel versus bevacizumab plus liposomal doxorubicin were hypertension (9.0% versus 13.9%) and proteinuria (3.0% versus 8.4%). CONCLUSIONS: Bevacizumab 10 mg/kg Q2W appears efficacious for patients with recurrent ovarian cancer, with a manageable toxicity profile. Approval of this regimen is clinically desirable for Japanese patients with ovarian cancer. |
format | Online Article Text |
id | pubmed-8520859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-85208592021-10-29 The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke Int J Clin Oncol Original Article BACKGROUND: Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients with platinum-resistant recurrent ovarian cancer. In this retrospective analysis, we evaluated the usage patterns of bevacizumab administered for platinum-resistant recurrent ovarian cancer. METHODS: We obtained clinical data from 155 Japanese medical facilities between November 2013 and December 2018 via a survey. Items included the number of cases of platinum-resistant recurrent ovarian cancer treated with bevacizumab according to dosage. For regimens including bevacizumab 10 mg/kg Q2W, additional information was requested relating to concomitantly administered agents, and the efficacy and safety of the regimen. RESULTS: Of 1739 bevacizumab-containing regimens reported in 1633 patients with recurrent ovarian cancer, 264 used 10 mg/kg Q2W. The overall response rate (ORR) with this regimen was 26.1%. Response rates varied according to regimen and were particularly favorable when bevacizumab 10 mg/kg Q2W was administered with paclitaxel (ORR, 53.0%) versus liposomal doxorubicin (15.0%; P < 0.0001) and irinotecan (7.7%; P < 0.028). The most frequent Grade ≥ 3 adverse events associated with bevacizumab 10 mg/kg Q2W were neutropenia (11.7%) and hypertension (11.7%). The most frequent bevacizumab-associated Grade ≥ 3 adverse events with bevacizumab plus paclitaxel versus bevacizumab plus liposomal doxorubicin were hypertension (9.0% versus 13.9%) and proteinuria (3.0% versus 8.4%). CONCLUSIONS: Bevacizumab 10 mg/kg Q2W appears efficacious for patients with recurrent ovarian cancer, with a manageable toxicity profile. Approval of this regimen is clinically desirable for Japanese patients with ovarian cancer. Springer Singapore 2021-07-26 2021 /pmc/articles/PMC8520859/ /pubmed/34308512 http://dx.doi.org/10.1007/s10147-021-01996-8 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
title | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
title_full | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
title_fullStr | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
title_full_unstemmed | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
title_short | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
title_sort | efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520859/ https://www.ncbi.nlm.nih.gov/pubmed/34308512 http://dx.doi.org/10.1007/s10147-021-01996-8 |
work_keys_str_mv | AT sekinemasayuki theefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT enomototakayuki theefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT watanabeyoh theefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT katabuchihidetaka theefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT yaegashinobuo theefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT aokidaisuke theefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT sekinemasayuki efficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT enomototakayuki efficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT watanabeyoh efficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT katabuchihidetaka efficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT yaegashinobuo efficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT aokidaisuke efficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer |